Last reviewed · How we verify

A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients With Advanced Cancer

NCT00632931 Phase 1 COMPLETED Results posted

A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval in patients with relapsed or refractory advanced cancer.

Details

Lead sponsorMerck Sharp & Dohme LLC
PhasePhase 1
StatusCOMPLETED
Enrolment25
Start date2007-07
Completion2009-04

Conditions

Interventions

Primary outcomes